Key result
Besides CYP2C19*2, carriage of the CYP2C9*3 variant allele was associated with poor clopidogrel response in patients receiving a 300 mg loading dose (OR 11.1; 95% CI 1.6-78.8; P=0.016).
Why the study?
Do genetic variants CYP2C19*2 and CYP2C9*3 increase on-clopidogrel platelet reactivity in patients undergoing elective coronary stenting?
Population
428 consecutive patients undergoing elective coronary stenting on dual antiplatelet therapy.
Comparison
Carriage of genetic variants affecting… vs Non-carriers of the respective genetic variants.
Design
Cohort
Authors
Loading...
CYP2C9*3 carriage may identify additional clopidogrel poor responders; extends pharmacogenetic data but remains hypothesis-generating.
Observational (n=428)
Do genetic variants CYP2C19*2 and CYP2C9*3 increase on-clopidogrel platelet reactivity in patients undergoing elective coronary stenting?
Odds Ratio: 11.1 (95% CI 1.6–78.8)
p-value: p=0.016
The CYP2C9*3 variant allele, alongside CYP2C19*2, is associated with higher on-clopidogrel platelet reactivity and poor responder status in patients undergoing elective coronary stenting.
Harmsze et al. (2009) conducted an observational in Elective coronary stenting on dual antiplatelet therapy (n=428). CYP2C9*3 and CYP2C19*2 variant alleles vs. Non-carriers was evaluated on Poor responder status (high platelet reactivity) in the 300 mg clopidogrel loading dose group (OR 11.1, 95% CI 1.6-78.8, p=0.016). Besides CYP2C19*2, carriage of the CYP2C9*3 variant allele was associated with poor clopidogrel response in patients receiving a 300 mg loading dose (OR 11.1; 95% CI 1.6-78.8; P=0.016).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: